Navigation Links
FDLI, PEN co-sponsor major conference on nanotechnology
Date:12/10/2007

Nanotechnology was incorporated into more than $50 billion in manufactured goods last year, according to Lux Research. By 2014, the market will grow to $2.6 trillion. By 2011, over $15 billion in nano-enabled drugs and therapeutics will be soldup from more than $3 billion in 2006. And industry experts project that nanotechnology will be incorporated into $20 billion worth of consumer food products by 2010.

Yet, despite this rapid commercialization, no nano-specific regulation exists anywhere in the world. Most regulatory agencies remain in an information-gathering modelacking the legal and scientific tools, information and resources they need to adequately oversee exponential nanotechnology market growth.

Now, for the first time, top officials at the agencies responsible for the regulation of nanotechnology productsincluding the Food and Drug Administration, Environmental Protection Agency, Occupational Safety and Health Administration and Department of Agriculturewill meet at a Food and Drug Law Institute conference to discuss their plans for managing and monitoring these products.

At FDLIs 1st Annual Conference on Nanotechnology Law, Regulation and Policy, February 28-29, 2008, at the LEnfant Plaza Hotel, in Washington, DC, food and drug industry representatives also will find out whats happening internationally on nanotech regulation, how venture capitalists look at the future of nanotechnology and what the leading corporations, scientific laboratories and academic centers are focusing on in this dynamic field.

This groundbreaking conference, co-sponsored by the Woodrow Wilson International Center for Scholars Project on Emerging Nanotechnologies, in partnership with Arizona State University and the Burdock Group, will address the crucial issues surrounding nanotechnology law, regulation and policy, including:

  • What first and second generation nanotechnology products already are on the market, and what is to come?
  • Is Congress ready to act on nanotechnology if federal regulators do not?
  • Do Europe and Asia approach nanotechnology safety and oversight differently than the United States?
  • How do consumers see nanoproducts?
  • When it comes to nanotechnology, should size make a regulatory difference?

Michael Taylor, Research Professor of Health Policy, School of Public Health and Health Services, The George Washington University, and author of the most comprehensive report published on nanotechnology regulation at FDA, Regulating the Products of Nanotechnology, Does FDA Have the Tools It Needs?, will present the keynote address. Also, Sen. Ron Wyden (D-Ore.), co-chair of the Congressional Nanotechnology Caucus, and invited luncheon speaker, will discuss future congressional actions in this area.

Top-level FDA officials, including Associate Commissioner for Science Norris Alderson; Deputy Commissioner for Policy Randall W. Lutter; Deputy Associate General Counsel Jeffrey Senger; and Director of Food Additive Safety Laura Tarantino, will appear on a special panel on FDA regulation of nanotechnology.

Other featured speakers and moderators include:

Jay M. Ansell, Personal Care Products Council;
Susan D. Brienza, Of Counsel, Patton Boggs LLP;
George Burdock, President, Burdock Group;
Robert W. Carpick; University of Pennsylvania Director, The Nanotechnology Institute;
Ricardo Carvajal; Counsel, Reed Smith LLP;
Jim Czaban, Partner, WilmerHale;
Lee Farrow, Senior Vice President, ACE Medical Risk;
Piotr Grodzinski, Director, NCI Alliance for Nanotechnology in Cancer, NIH;
Ralph Hall, Professor, University of Minnesota Law School;
Robert A. Hoerr, President & CEO, Nanocopoeia, Inc.;
Michael Holman. Senior Analyst, Lux Research;
Karen Hunter, Program Specialist, U.S. Department of Agriculture, Cooperative State Research, Education and Extension Service;
Rachel G. Lattimore, Partner, Arent Fox LLP;
Scott Livingston, Managing Director, Axiom Capital Management/The Livingston Group;
Jane Macoubrie, President, Embry Research;
Ellen Maldenado, Attorney-at-Law;
Gary Marchant, Lincoln Professor of Emerging Technologies, Law & Ethics
Sandra Day OConnor College of Law;
Philippe Martin, Principal Administrator, Nanotechnologies Policy Development and Coordination, Consumer Protection Directorate (DG-SANCO), European Commission;
Terry L. Medley, Global Director, Corporate Regulatory Affairs, DuPont Environment and Sustainable Growth Center;
Julia A. Moore, Deputy Director, Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars;
Sean Murdock, Executive Director, NanoBusiness Alliance;
Fern P. OBrian, Partner, Arnold & Porter LLP;
Leon Radomsky, Chair, Nanotechnology Industry Team, Foley & Lardner LLP;
David W. Rejeski, Director, Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars;
Stephanie Scharf, Partner, Schoeman Updike Kauffman & Scharf;
Dietram Scheufele, Professor of Life Sciences Communication, University of Wisconsin;
Loretta Schuman, Occupational Safety and Health Administration;
Laura Sciarrino, Vice President, Legal, CV Therapeutics, Inc.; and
Jim Willis, U.S. Environmental Protection Agency.


'/>"/>

Contact: Michael Levin-Epstein
mdl@fdli.org
202-222-0897
Project on Emerging Nanotechnologies
Source:Eurekalert

Related biology news :

1. deCODE discovers cause of major subtype of glaucoma
2. Bleeding, not inflammation, is major cause of early lung infection death
3. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
4. Leading experts cite poor health and nutrition as major barrier to education in developing world
5. Majority of Americans want local action on global warming, says poll
6. How schizophrenia develops: Major clues discovered
7. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
8. NIH selects LIAI for major study on allergy molecular causes and possible treatments
9. Local sources major cause of US near-ground aerosol pollution
10. Tree of life for flowering plants reveals relationships among major groups
11. Humans not the major target of Shiga toxin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2020)... ... March 05, 2020 , ... In September ... The AlphaSTEM Test™ is the first, and still only, available technology that ... that attempt to provide information about the number and quality of therapeutic tissue ...
(Date:3/4/2020)... ... March 04, 2020 , ... VGXI, Inc., ... it has been nominated as a finalist in the category of Best Contract ... as VGXI expedites manufacturing of a DNA vaccine against the novel coronavirus, COVID-19, ...
(Date:3/3/2020)... N.D. (PRWEB) , ... March 03, 2020 , ... Board-certified ... in Fargo, ND. With over 16 years of training and experience, Dr. Noffze can ... teeth. Removing wisdom teeth as soon as possible is beneficial to the oral and ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... February 21, 2020 , ... Join Forrest Brown, Engineering ... of Sequence, Inc. for an informative session on Wednesday, February ... Flexibility: Key elements to incorporate into facility design to add manufacturing flexibility in the ...
(Date:2/19/2020)... ... February 19, 2020 , ... Red Nucleus, a leading provider ... announced the opening of a new office in Tokyo, Japan. The new office ... Nucleus announced the new office in response to customer requests for regional coverage. ...
(Date:2/10/2020)... ... February 10, 2020 , ... R3 Medical Training announced it is ... 2020 in Las Vegas. The course is hands on involving real patients and stem ... few years, the Comprehensive Stem Cell Training Course has received rave reviews from attendees, ...
(Date:2/3/2020)... CAMBRIDGE, Mass. (PRWEB) , ... February 03, 2020 ... ... with US offices in Cambridge, MA, announce that OmniType, the 11-locus, single tube ... from today. OmniType is a best-in-class product featuring locus-multiplexing and short library preparation, ...
Breaking Biology Technology: